Price T Rowe Associates Inc Seres Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $816 Billion
- Q1 2024
A detailed history of Price T Rowe Associates Inc transactions in Seres Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 298,111 shares of MCRB stock, worth $214,639. This represents 0.0% of its overall portfolio holdings.
Number of Shares
298,111
Previous 363,650
18.02%
Holding current value
$214,639
Previous $510,000
54.51%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding MCRB
# of Institutions
100Shares Held
62.7MCall Options Held
36.9KPut Options Held
476K-
Flagship Pioneering Inc. Cambridge, MA23.1MShares$16.6 Million1.17% of portfolio
-
Black Rock Inc. New York, NY6.83MShares$4.91 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.73MShares$4.85 Million0.0% of portfolio
-
Hudson Bay Capital Management LP Greenwich, CT5.43MShares$3.91 Million0.03% of portfolio
-
Geode Capital Management, LLC Boston, MA2.13MShares$1.54 Million0.0% of portfolio
About Seres Therapeutics, Inc.
- Ticker MCRB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 124,072,000
- Market Cap $89.3M
- Description
- Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...